Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

630 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
GBD 2021 Diseases and Injuries Collaborators. GBD 2021 Diseases and Injuries Collaborators. Lancet. 2024 Apr 15:S0140-6736(24)00757-8. doi: 10.1016/S0140-6736(24)00757-8. Online ahead of print. Lancet. 2024. PMID: 38642570 Free article.
Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial-Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Ductal Adenocarcinoma.
Guinn S, Kinny-Köster B, Tandurella JA, Mitchell JT, Sidiropoulos DN, Loth M, Lyman MR, Pucsek AB, Zabransky DJ, Lee JW, Kartalia E, Ramani M, Seppälä TT, Cherry C, Suri R, Zlomke H, Patel J, He J, Wolfgang CL, Yu J, Zheng L, Ryan DP, Ting DT, Kimmelman A, Gupta A, Danilova L, Elisseeff JH, Wood LD, Stein-O'Brien G, Kagohara LT, Jaffee EM, Burkhart RA, Fertig EJ, Zimmerman JW. Guinn S, et al. Cancer Res. 2024 May 2;84(9):1517-1533. doi: 10.1158/0008-5472.CAN-23-1660. Cancer Res. 2024. PMID: 38587552
Isolation and characterization of dihydrohomoisoflavonoids from Portulaca oleracea L.
Liu J, Wang H, Shao H, Sun J, Dong C, Chen R, Kang J. Liu J, et al. Phytochemistry. 2024 Jun;222:114071. doi: 10.1016/j.phytochem.2024.114071. Epub 2024 Mar 28. Phytochemistry. 2024. PMID: 38552709
The 50% EtOH fraction from the 70% EtOH extract prevented HepG2 human liver cancer cell damage induced by N-acetyl-p-aminophenol (APAP), and the cell survival rate was 62.3%. Portulacaside B (6a), which was isolated from the 50% EtOH fraction, exhibited hepatoprotective an …
The 50% EtOH fraction from the 70% EtOH extract prevented HepG2 human liver cancer cell damage induced by N-acetyl-p-aminophenol (APA …
Dual elemental doping activated signaling pathway of angiogenesis and defective heterojunction engineering for effective therapy of MRSA-infected wounds.
Huang J, Wu S, Wang Y, Shen J, Wang C, Zheng Y, Chu PK, Liu X. Huang J, et al. Bioact Mater. 2024 Mar 14;37:14-29. doi: 10.1016/j.bioactmat.2024.03.011. eCollection 2024 Jul. Bioact Mater. 2024. PMID: 38515610 Free PMC article.
Furthermore, the formation of an internal electric field at the ternary heterogeneous interface optimizes the charge transfer pathway, inhibits the recombination of electron-hole pairs, improves the photodynamic effect of g-C(3)N(4), and enhances its catalytic performance. Theref …
Furthermore, the formation of an internal electric field at the ternary heterogeneous interface optimizes the charge transfer pathway, inhib …
Phase Behavior of the Mixtures of 2- and 3-Components for Poly(styrene-co-octafluoropentyl methacrylate) by Dispersion Polymerization under CO2.
Behera US, Baskaran D, Byun HS. Behera US, et al. ACS Omega. 2024 Feb 26;9(10):11910-11924. doi: 10.1021/acsomega.3c09665. eCollection 2024 Mar 12. ACS Omega. 2024. PMID: 38496977 Free PMC article.
The phase equilibrium curves were obtained for p(styrene-co-OFPMA) [30:1; 1.0% (M(w) = 42,400), 2.0% (M(w) = 33,800), and 4.0% (M(w) = 24,100); AIBN: 1.0 wt %] + sc-C(3)H(6), sc-C(4)H(8), and sc-CHClF(2) mixtures. These curves exhibited an increasing s …
The phase equilibrium curves were obtained for p(styrene-co-OFPMA) [30:1; 1.0% (M(w) = 42,400), 2.0% (M(w) = 33,800), a …
Testing SIPA1L2 as a modifier of CMT1A using mouse models.
Murray GC, Hines TJ, Tadenev ALD, Xu I, Züchner S, Burgess RW. Murray GC, et al. J Neuropathol Exp Neurol. 2024 Apr 19;83(5):318-330. doi: 10.1093/jnen/nlae020. J Neuropathol Exp Neurol. 2024. PMID: 38472136
To validate SIPA1L2 as a candidate modifier and to assess its potential as a therapeutic target, we engineered mice with deletion of exon 1 (including the start codon) of the Sipa1l2 gene and crossed them to the C3-PMP22 mouse model of CMT1A. Neuromuscular phenotyping show …
To validate SIPA1L2 as a candidate modifier and to assess its potential as a therapeutic target, we engineered mice with deletion of exon 1 …
Physical Activity in Cerebral Palsy: A Current State Study.
Molina-Cantero AJ, Pousada García T, Pacheco-da-Costa S, Lebrato-Vázquez C, Mendoza-Sagrera A, Meriggi P, Gómez-González IM. Molina-Cantero AJ, et al. Healthcare (Basel). 2024 Feb 23;12(5):535. doi: 10.3390/healthcare12050535. Healthcare (Basel). 2024. PMID: 38470646 Free PMC article.

Findings reveal that only a 17.6% meets the World Health Organization (WHO) recommendations regarding regular physical activity (RPA), decreasing in frequency or number of days a week, (3.7 d/w to 2.9 d/w; p < 0.01) and duration (50.5 min/d to 45.2 min/d;

…
Findings reveal that only a 17.6% meets the World Health Organization (WHO) recommendations regarding regular physical activity (RPA), decre …
Interleukin-6 as a Predictive Factor of Pathological Response to FLOT Regimen Systemic Treatment in Locally Advanced Gastroesophageal Junction or Gastric Cancer Patients.
Marcisz-Grzanka K, Kotowicz B, Nowak A, Winiarek M, Fuksiewicz M, Kowalska M, Tysarowski A, Olesinski T, Palucki J, Sulkowska U, Kolasinska-Cwikla A, Wyrwicz LS. Marcisz-Grzanka K, et al. Cancers (Basel). 2024 Feb 12;16(4):757. doi: 10.3390/cancers16040757. Cancers (Basel). 2024. PMID: 38398148 Free PMC article.
Circulating tumour cells (CTCs) and interleukin-1beta (IL-1beta), interleukin-6 (IL-6), interleukin-8 (IL-8), and interleukin-10 (IL-10) were measured in a pilot group of 40 patients at baseline and before cycle two (C2) and cycle three (C3). RESULTS: Of all the measured p …
Circulating tumour cells (CTCs) and interleukin-1beta (IL-1beta), interleukin-6 (IL-6), interleukin-8 (IL-8), and interleukin-10 (IL-10) wer …
630 results